New Product in Development Looks to Help Patients with Clostridium Difficile

OCTOBER 19, 2015
Amy Jacob
In the world of gastrointestinal conditions clostridium difficile, or c-diff is becoming a more common condition confronting doctors. Finding the best treatment method remains to be seen.

Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine discussed the development of one such potential treatment option being developed during the annual ID Week conference in San Diego. 




Related Coverage >>>
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.